MiMedx Group, Inc $MDXG Shares Bought by American Century Companies Inc.

American Century Companies Inc. grew its holdings in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 36.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 270,808 shares of the company's stock after acquiring an additional 71,739 shares during the period. American Century Companies Inc. owned about 0.18% of MiMedx Group worth $2,058,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in shares of MiMedx Group by 15.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after purchasing an additional 238,075 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of MiMedx Group during the 4th quarter worth $450,000. Raymond James Financial Inc. purchased a new stake in shares of MiMedx Group during the 4th quarter worth $887,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of MiMedx Group by 18.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,713 shares of the company's stock worth $302,000 after purchasing an additional 6,090 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after purchasing an additional 2,837 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald lifted their price objective on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. Wall Street Zen raised shares of MiMedx Group from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $12.00.

MiMedx Group Stock Performance

NASDAQ MDXG traded up $0.05 during trading hours on Friday, hitting $7.14. 366,086 shares of the stock were exchanged, compared to its average volume of 458,070. The company has a market cap of $1.06 billion, a price-to-earnings ratio of 34.00 and a beta of 1.74. MiMedx Group, Inc has a 12-month low of $5.47 and a 12-month high of $10.14. The stock has a 50-day moving average of $6.90 and a 200 day moving average of $7.00. The company has a quick ratio of 3.90, a current ratio of 4.39 and a debt-to-equity ratio of 0.08.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.04. The firm had revenue of $98.61 million during the quarter, compared to analysts' expectations of $90.79 million. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. As a group, equities research analysts forecast that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.